MoonLake Immunotherapeutics (MLTX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, MoonLake Immunotherapeutics (MLTX) has a cash flow conversion efficiency ratio of -0.261x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-66.29 Million) by net assets ($254.02 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see MoonLake Immunotherapeutics market capitalisation for the company's overall valuation and market capitalisation.
MoonLake Immunotherapeutics - Cash Flow Conversion Efficiency Trend (2020–2025)
This chart illustrates how MoonLake Immunotherapeutics's cash flow conversion efficiency has evolved over time, based on yearly financial data.
MoonLake Immunotherapeutics Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of MoonLake Immunotherapeutics ranked by their cash flow conversion efficiency. See MoonLake Immunotherapeutics debt service capacity to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Shijiazhuang Kelin Elec Co
SHG:603050
|
0.182x |
|
Blue Jet Healthcare Limited
NSE:BLUEJET
|
0.152x |
|
Kunshan Guoli Electronic Technology Co Ltd
SHG:688103
|
0.012x |
|
Zhejiang Wansheng Co Ltd
SHG:603010
|
0.039x |
|
Obsidian Therapeutics, Inc. Common Stock
NASDAQ:OBX
|
0.080x |
|
Winmark Corporation
NASDAQ:WINA
|
-0.285x |
|
Ampoc Far-East Co Ltd
TW:2493
|
0.115x |
|
Shandong Head Co Ltd
SHE:002810
|
0.027x |
Annual Cash Flow Conversion Efficiency for MoonLake Immunotherapeutics (2020–2025)
The table below shows the annual cash flow conversion efficiency of MoonLake Immunotherapeutics from 2020 to 2025. View MoonLake Immunotherapeutics (MLTX) share price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $304.48 Million | $-196.01 Million | -0.644x | -150.34% |
| 2024-12-31 | $453.39 Million | $-116.59 Million | -0.257x | -208.67% |
| 2023-12-31 | $513.49 Million | $-42.78 Million | -0.083x | +89.75% |
| 2022-12-31 | $68.77 Million | $-55.89 Million | -0.813x | -126.91% |
| 2021-12-31 | $-11.65 Million | $-35.18 Million | 3.021x | +107387.54% |
| 2020-12-31 | $112.48 Million | $-316.69K | -0.003x | -- |
About MoonLake Immunotherapeutics
MoonLake Immunotherapeutics, a clinical-stage biotechnology company, focuses on developing therapies for inflammatory skin and joint diseases. It develops Sonelokimab, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody for the treatment of inflammatory diseases in dermatology and rheumatology, as well as for hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, palmoplan… Read more